secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cartesian Therapeutics, Inc. (RNAC)
CIK:        0001453687
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001140361-24-001205
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cartesian reports positive 12-month Phase 2a data for Descartes-08 in MG; cash $118M
--------------------------------------------------------------------------------

- 12-month follow-up: 5 of 7 Phase 2a MG patients maintained clinically meaningful improvements ~10 months after last infusion; autoantibodies durably reduced.
- Descartes-08 well-tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity; outpatient administration without lymphodepletion.
- Phase 2b topline data expected mid-2024; Phase 2 study in SLE to initiate 1H24; IND cleared for next-gen Descartes-15 for multiple myeloma.
- Pro forma cash ~$118M as of Dec 31, 2023; expected to fund operations into 2H 2026, through Phase 3 of Descartes-08.
- Common shares outstanding: 161.9M; Series A preferred convertible into ~534.3M common shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1453687/000114036124001205/0001140361-24-001205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1453687/000114036124001205/ny20014884x2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-001205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer